A COVID-19 antibody treatment developed by a South Korean pharmaceutical company has been approved by the Ministry of Food and Drug Safety and is ready for use.
But SINCE it’s STILL going through a third clinical trial, Celltrion’s drug will be limited to critically ill patients in certain hospitals THAT MADE SPECIAL REQUESTS.
Aside from Celltrion, South Korea’s Green Cross Pharma has also had its COVID-19 treatment authorized for special use.
As of Tuesday, around 40 people are registered for phase two trials for COVID-19 treatments, and almost five thousand people have donated their antibodies to help others fight COVID-19.

Reporter : jychoi@arirang.com

arirang

Source Link

This page is made available thanks to China Press Release by Topic News

Leave a Reply

Your email address will not be published.